Part 6 - Optimal Management of EGFR Mutation Positive Advanced Lung Cancer - Dr Shyam Aggarwal

Dacomitinib: new treatment paradigm in the management of EGFR mutation positive NSCLCПодробнее

NSCLC WITH EGFR MUTATION - STATUS UPDATEПодробнее

Multi Modality Management of Lung CancerПодробнее

Part 6 - Optimal Management of EGFR Mutation Positive Advanced Lung Cancer - Dr Shyam AggarwalПодробнее

2021 West Oncology | Lung Cancer | EGFR Mutation Therapy Resistance and ADCs and TROP2Подробнее

Part 4 - Optimal management of EGFR m NSCLC patients - Dr. Shyam Agarwal, DelhiПодробнее

Management of Epidermal Growth Factor Receptor (EGFR) - Mutated Non-small-cell Lung Cancer (NSCLC)Подробнее

Advancing Care for Patients With EGFR Mutation–Positive NSCLC: Precision Medicine StrategiesПодробнее

EGFR mutation positive tumors: Treatment strategies in front line and at relapseПодробнее

Should Avastin be Added to EGFR TKI Therapy for EGFR Mutation-Positive NSCLC?Подробнее

Emerging Data in EGFR-Mutant Lung CancerПодробнее

Osimertinib as First-Line Treatment for EGFR Mutation-Positive Advanced NSCLC? (BMIC-017)Подробнее

Part 9 - Panel Discussion Metastatic Lung Cancer - Role of Targeted Agents & Immunotherapy- Dr UllasПодробнее

Do immune checkpoint inhibitors work in EGFR mutant lung cancer?Подробнее

Interview with Jonathan Goldman, MD: Management of Non-Small Cell Lung Cancer with an EGFR MutationПодробнее

eCME on Treatment options for EGFR Mutant Advanced NSCLCПодробнее

Next Generation Sequencing for EGFR Mutant Lung Cancer: How it Guides Treatment Today & TomorrowПодробнее